Publicly funded influenza vaccine products

2025/2026 Fall Season:  

All 2025/26 influenza vaccines are trivalent products and do not include the B/Yamagata component as this lineage has not been detected globally since March 2020. Per NACI’s Statement on seasonal influenza vaccines for 2025-2026, expert groups have endorsed the exclusion of the B/Yamagata component from influenza vaccine formulations. 

BCCDC Part 4 – Biological Products -  Influenza vaccines: 

• Flumist® 
• Fluviral® 
• Fluzone® 
• Fluad® 

The intended use of these vaccines by age group can be found here. 

See Patient Eligibility Criteria for information on the eligibility. 

Resources: 

• BCCDC Immunization Guidelines – Influenza vaccines 
• 2025/26 Season Influenza Vaccine Eligibility   
• Safety issues application to influence vaccine 
• Intended use of influenza vaccine